Abstract
To assess the safety and efficacy of nonmyeloablative allogeneic transplantation in patients with HIV infection, a clinical protocol was initiated in patients with refractory hematologic malignancies and concomitant HIV infection. The results from the first 2 patients are reported. The indications for transplantation were treatment-related acute myelogenous leukemia and primary refractory Hodgkin disease in patients 1 and 2, respectively. Only patient 1 received genetically modified cells. Both patients tolerated the procedure well with minimal toxicity, and complete remissions were achieved in both patients, but patient 2 died of relapsed Hodgkin disease 12 months after transplantation. Patient 1 continues in complete remission with undetectable HIV levels and rising CD4 counts, and with both the therapeutic and control gene transfer vectors remaining detectable at low levels more than 2 years after transplantation. These results suggest that nonmyeloablative allogeneic transplantation in the context of highly active antiretroviral therapy is feasible in patients with treatment-sensitive HIV infection.
Original language | English |
---|---|
Pages (from-to) | 698-701 |
Number of pages | 4 |
Journal | Blood |
Volume | 99 |
Issue number | 2 |
Publication status | Published - 15 Jan 2002 |
Keywords
- Acquired Immunodeficiency Syndrome
- Acute Disease
- Adult
- Anti-Bacterial Agents
- Antiretroviral Therapy, Highly Active
- Cyclophosphamide
- Cyclosporine
- Feasibility Studies
- Ganciclovir
- Graft vs Host Disease
- Hematopoietic Stem Cell Transplantation
- Hodgkin Disease
- Humans
- Infection Control
- Leukemia, Myeloid
- Prednisone
- Premedication
- Recurrence
- Remission Induction
- Transplantation Conditioning
- Treatment Outcome
- Vidarabine
- Viral Load
- Journal Article